Gossamer Bio, Inc.
GOSS · NASDAQ
Market closed$0.170100$-0.000400 (-0.23%)After hours $0.177400 · +4.29%
Key statistics
Previous close$0.170500
Open$0.162700
Day high$0.176900
Day low$0.160300
52-week high$3.87
52-week low$0.114000
Market cap39.90M
Volume11.56M
Average volume13.98M
P/E ratio-0.22
Forward P/E—
EPS-0.79
Dividend yield0.00%
Market context
Why it moved
GOSS experienced a marginal decline today, with no significant company-specific news identified as a clear catalyst, suggesting the slight dip reflects routine market fluctuations and thin trading sentiment rather than any major fundamental development.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 15, 2026Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0BStock Titan · July 1, 2026Gossamer Bio fixes note conversion at $0.19, warrants at $0.34Investing.com · June 26, 2026H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchangeBusiness Wire · June 17, 2026Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesStock Titan · June 17, 2026Investors swap $181M of Gossamer 2027 debt for new notes, stockGlobeNewswire · May 20, 2026Robbins LLP Reminds GOSS Investors of the Pending ClassClinical Trials Arena · February 24, 2026Gossamer Bio reports topline Phase III PROSERA outcomes for PAHStocktwits · February 23, 2026Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? Benzinga · June 17, 2026Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity Mt Newswire · June 3, 2026Gossamer Bio Reports Early Tender Results for Exchange Offer Mt Newswire · June 2, 2026Gossamer Bio Extends Early Tender Deadline for Exchange of Convertible Notes due 2027 Benzinga · May 18, 2026Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript Benzinga · May 18, 2026Gossamer Bio Launches Exchange Offer For $72M New 7.5% Notes, Up To 317.6M Shares/Prefunded Warrants, Plus Early Tender Purchase Warrants Benzinga · May 18, 2026Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate Mt Newswire · March 23, 2026Cantor Fitzgerald Downgrades Gossamer Bio to Neutral From Overweight Benzinga · March 23, 2026Cantor Fitzgerald Downgrades Gossamer Bio to Neutral